Venetoclax in combination with trametinib has been proposed as targeted therapy in RAS-mutated AML [16], combinations of STAT5- and MCL-1 inhibitors in FLT3- or TET2-mutated AML [17]. Here, MCL1 is linked to acute myeloid leukemia.